(Q34548787)

3 August 2017

1 reference

title

Australian and New Zealand clinical practice guidelines for the treatment of depression (English)

1 reference

3 August 2017

0 references

Peter Ellis

1

1 reference

PubMed ID

15209830

3 August 2017

Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression

series ordinal

2

1 reference

3 August 2017

1 June 2004

1 reference

Australian and New Zealand Journal of Psychiatry

3 August 2017

1 reference

3 August 2017

38

1 reference

3 August 2017

6

1 reference

3 August 2017

389-407

1 reference

Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses

3 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Depression. Underrecognition and undertreatment by psychiatrists and other health care professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Epidemiological data suggest antidepressants reduce suicide risk among depressives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Poverty, unemployment, and common mental disorders: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Birth cohort trends in major depression: increasing rates and earlier onset in New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Impact of major depression on chronic medical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Psychological stress and depression in older patients with intravenous drug use and human immunodeficiency virus infection: implications for intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Climatic and diurnal variation in suicide attempts in the ED.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Diurnal variations in suicide by age and gender in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Counselling and interpersonal therapies for depression: towards securing an evidence-base

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Does increasing dose improve efficacy in patients with poor antidepressant response: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

'New' and 'old' antidepressants: all equal in the eyes of the lore?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Cognitive Therapy and Pharmacotherapy for Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Antidepressant specificity in atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Atypical features and treatment response in the National Institute of Mental Health Treatment of Depression Collaborative Research Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

The pharmacological treatment of delusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

How well do antidepressants work in older people? A systematic review of Number Needed to Treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Considerations for the use of antidepressants in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Impact of lipodystrophy on the quality of life of HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Depression and cardiac mortality: results from a community-based longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Treating depression in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

A possible interaction between lithium and rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Are fish oils an effective therapy in mental illness--an analysis of the data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Classifying depression: should paradigms lost be regained?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Atypical depression: a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

National Institute of Mental Health Treatment of Depression Collaborative Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Increased serum soluble CD8 or suppressor/cytotoxic antigen concentrations in depression: suppressive effects of glucocorticoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

How long should pindolol be associated with paroxetine to improve the antidepressant response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Fluoxetine in the prevention of depressive recurrences: a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Comparison of St John's wort and imipramine for treating depression: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2004.01377.X

10.1111/J.1440-1614.2004.01377.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

15209830